LTI0
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more
LTI0 (LTI0) - Net Assets
Latest net assets as of September 2025: €-19.45 Million EUR
Based on the latest financial reports, LTI0 (LTI0) has net assets worth €-19.45 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.34 Million) and total liabilities (€25.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-19.45 Million |
| % of Total Assets | -306.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 29.26 |
LTI0 - Net Assets Trend (2021–2024)
This chart illustrates how LTI0's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LTI0 (2021–2024)
The table below shows the annual net assets of LTI0 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-4.54 Million | -56.60% |
| 2023-12-31 | €-2.90 Million | -107.69% |
| 2022-12-31 | €37.74 Million | -49.16% |
| 2021-12-31 | €74.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LTI0's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11846000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €536.42 Million | % |
| Total Equity | €-4.54 Million | 100.00% |
LTI0 Competitors by Market Cap
The table below lists competitors of LTI0 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MODIVCARE INC. DL-001
F:PRF0
|
$2.91 Million |
|
Joy Industrial Co., Ltd.
TWO:4559
|
$2.91 Million |
|
INVO Bioscience Inc
NASDAQ:INVO
|
$2.91 Million |
|
InnSuites Hospitality Trust
NYSE MKT:IHT
|
$2.91 Million |
|
Sulliden Minerals SA
TO:SMC
|
$2.90 Million |
|
Hayasa Metals Inc.
V:HAY
|
$2.90 Million |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
$2.90 Million |
|
Magnasense AB
ST:MAGNA
|
$2.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LTI0's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,901,000 to -4,543,000, a change of -1,642,000.
- Net loss of 25,430,000 reduced equity.
- Share repurchases of 21,000 reduced equity.
- New share issuances of 23,407,000 increased equity.
- Other factors increased equity by 402,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-25.43 Million | -559.76% |
| Share Repurchases | €21.00K | -0.46% |
| Share Issuances | €23.41 Million | +515.23% |
| Other Changes | €402.00K | +8.85% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares LTI0's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €362.26 | €1.39 | x |
| 2022-12-31 | €183.87 | €1.39 | x |
| 2023-12-31 | €-10.96 | €1.39 | x |
| 2024-12-31 | €-2.26 | €1.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LTI0 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-49.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -88.04% | 0.00% | 0.00x | 1.11x | €-72.78 Million |
| 2022 | -110.82% | 0.00% | 0.00x | 1.35x | €-45.60 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-50.92 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-24.98 Million |
Industry Comparison
This section compares LTI0's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LTI0 (LTI0) | €-19.45 Million | -88.04% | N/A | $2.91 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |